Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer

British Journal of Cancer

Volumn 113, Issue 12, 2015, Pages 1730-1734

  Amatu, Alessio ^a   Somaschini, Alessio ^b   Cerea, Giulio ^a   Bosotti, Roberta ^b   Valtorta, Emanuele ^a   Buonandi, Pasquale ^a   Marrapese, Giovanna ^a   Veronese, Silvio ^a   Luo, David ^c   Hornby, Zachary ^c   Multani, Pratik ^c   Murphy, Danielle ^c   Shoemaker, Robert ^c   Lauricella, Calogero ^a   Giannetta, Laura ^a   Maiolani, Martina ^a   Vanzulli, Angelo ^a   Ardini, Elena ^b   Galvani, Arturo ^b   Isacchi, Antonella ^b   Sartore Bianchi, Andrea ^a   Siena, Salvatore ^a,d   more..

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b NERVIANO MEDICAL SCIENCES   (Italy)

^c Ignyta   (United States)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

ALK; CAD ALK; colorectal cancer; Entrectinib; gene fusions

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ASPARTATE CARBAMOYLTRANSFERASE; BEVACIZUMAB; CARBAMOYL PHOSPHATE SYNTHASE (GLUTAMINE HYDROLYSING); CASPASE ACTIVATED DEOXYRIBONUCLEASE; DIHYDROOROTASE; ENTRECTINIB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; CAD TRIFUNCTIONAL ENZYME; INDAZOLE DERIVATIVE; PROTEIN TYROSINE KINASE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CASE REPORT; CHROMOSOME 2; DISEASE COURSE; EXON; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENE REARRANGEMENT; HEMICOLECTOMY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPH NODE METASTASIS; METASTATIC COLORECTAL CANCER; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; NEXT GENERATION SEQUENCING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; COLORECTAL NEOPLASMS; GENETICS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; ASPARTATE CARBAMOYLTRANSFERASE; BENZAMIDES; CARBAMOYL-PHOSPHATE SYNTHASE (GLUTAMINE-HYDROLYZING); COLORECTAL NEOPLASMS; DIHYDROOROTASE; FEMALE; GENE REARRANGEMENT; HUMANS; INDAZOLES; MIDDLE AGED; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84952637567     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.401     Document Type: Article

References (20)

1. Aisner DL, Nguyen TT, Paskulin DD, Le AT, Haney J, Schulte N, Chionh F, Hardingham J, Mariadason J, Tebbutt N, Doebele RC, Weickhardt AJ, Varella-Garcia M (2014) ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. Mol Cancer Res 12: 111-118.
2. Ardini E, Bosotti R, Borgia AL, De Ponti C, Somaschini A, Cammarota R, Amboldi N, Raddrizzani L, Milani A, Magnaghi P, Ballinari D, Casero D, Gasparri F, Banfi P, Avanzi N, Saccardo MB, Alzani R, Bandiera T, Felder E, Donati D, Pesenti E, Sartore-Bianchi A, Gambacorta M, Pierotti MA, Siena S, Veronese S, Galvani A, Isacchi A (2014) The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol Oncol 8: 1495-1507.
3. Ardini E, Meninchicheri M, Banfi P, Casero D, Giorgini ML, Saccardo MB, Amboldi N, Avanzi N, Orsini P, Isacchi A, Presenti E, Galvani A (2013) The ALK inhibitor NMS-E628 also potently inhibits ROS1 and induces tumor regression in ROS-driven models. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 6-10 April 2013; Washington, DC. Cancer Res 73(8 Suppl): Abstract no. 2092.
4. Awad MM, Shaw AT (2014) ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol 12: 429-439.
5. Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A, Gambacorta M, Diaz LA, Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S (2013) Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 3: 658-673.
6. De Braud F, Pilla L, Niger M, Damian S, Bardazza B, Martinetti A, Pelosi G, Marrapese G, Palmeri L, Cerea G, Valtorta E, Veronese S, Sartore-Bianchi A, Ardini E, Martignoni M, Isacchi A, Luo D, Freddo L, Siena S (2014) RXDX-101, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. Ann Oncol 25: iv146-iv164.
7. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247.
8. Grande E, Bolós M-VV, Arriola E (2011) Targeting oncogenic ALK: a promising strategy for cancer treatment. Mol Cancer Ther 10: 569-579.
9. Grande-Garcá A, Lallous N, Dáz-Tejada C, Ramón-Maiques S (2013) Structure, functional characterization, and evolution of the dihydroorotase domain of human CAD. Structure 22: 185-198.
10. Lee J, Kim H, Hong J, Wang K, Kim S, Jang J, Kim S, Park J, Lim H, Kang W, Park Y, Lee J, Lee W, Park Y, Huh J, Yun S, Do I-G, Kim S, Balasubramanian S, Stephens P, Ross J, Li G, Hornby Z, Ali S, Miller V, Kim K-M, Ou S-H (2015) Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. Oncotarget 6(27): 24320-24332.
11. Medico E, Russo M, Picco G, Cancelliere C, Valtorta E, Corti G, Buscarino M, Isella C, Lamba S, Martinoglio B, Veronese S, Siena S, Sartore-Bianchi A, Beccuti M, Mottolese M, Linnebacher M, Cordero F, Di Nicolantonio F, Bardelli A (2015) The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nat Commun 6: 7002.
12. Richmond AL, Kabi A, Homer CR, Marina-Garcá N, Nickerson KP, Nesvizhskii AI, Sreekumar A, Chinnaiyan AM, Nuñez G, McDonald C (2012) The nucleotide synthesis enzyme CAD inhibits NOD2 antibacterial function in human intestinal epithelial cells. Gastroenterology 142: 1483-92.e6.
13. Sartore-Bianchi A, Ardini E, Bosotti R, Amatu A, Valtorta E, Somaschini A (2015) A novel LMNA-NTRK1 gene fusion confers sensitivity to entrectinib in metastatic colorectal cancer. J Natl Cancer Inst 108(1).
14. Siena S, Drillon A, Ou S-H, Farago A, Patel M, Bauer T, Hong D, Liu S, Lee J, Patel R, Schechet L, Luo D, Chow Maneval E, Multani P, De Braud F (2015a) Entrectinib (RXDX-101), an oral pan-Trk, ROS1, and ALK inhibitor in patients with advanced solid tumors harboring gene rearrangements. Eur J Cancer 51(Suppl 3): S724-S725.
15. Siena S, Sartore-Bianchi A, Lonardi S, Trusolino L, Martino C, Bencardino K, Leone F, Zagonel V, Torri V, Siravegna G, Amatu A (2015b) Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. J Clin Oncol 33: 3508.
16. Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A (2015) Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 21: 795-801.
17. Uhlén M, Fagerberg L, Hallström BMM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, Olsson I, Edlund K, Lundberg E, Navani S, Szigyarto CA, Odeberg J, Djureinovic D, Takanen JO, Hober S, Alm T, Edqvist P-HH, Berling H, Tegel H, Mulder J, Rockberg J, Nilsson P, Schwenk JM, Hamsten M, von Feilitzen K, Forsberg M, Persson L, Johansson F, Zwahlen M, von Heijne G, Nielsen J, Pontén F (2015) Proteomics. Tissue-based map of the human proteome. Science 347: 1260419.
18. Valtorta E, Martino C, Sartore-Bianchi A, Penaullt-Llorca F, Viale G, Risio M, Rugge M, Grigioni W, Lonardi S, Zagonel V, Leone F, Noe J, Ciardiello F, Pinto C, Labianca R, Mosconi S, Graiff C, Aprile G, Frau B, Garufi C, Loupakis F, Racca P, Tonini G, Lauricella C, Veronese S, Truini M, Siena S, Marsoni S, Gambacorta M (2015) Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol 28(11): 1481-1491.
19. Yaeger R, Cercek A, O'Reilly EM, Reidy DL, Kemeny N, Wolinsky T, Capanu M, Gollub MJ, Rosen N, Berger MF, Lacouture ME, Vakiani E, Saltz LB (2015) Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin Cancer Res 21: 1313-1320.
20. Zheng Z, Liebers M, Zhelyazkova B, Cao Y, Panditi D, Lynch KD, Chen J, Robinson HE, Shim HS, Chmielecki J, Pao W, Engelman JA, Iafrate AJ, Le LP (2014) Anchored multiplex PCR for targeted next-generation sequencing. Nat Med 20: 1479-1484.